Getting Your Patients Started on ENBREL: Financial Assistance and Insurance Verification

Whether your patients have private health insurance, are on Medicare, or are uninsured, we provide several options to help those with concerns about paying for ENBREL treatment.

You will need Adobe® Reader® to view certain documents on this page. If you do not already have it, download it for free from Adobe's website. Get Adobe® Reader®.

Prior Authorization Assistance

This simple form gives health care professionals an efficient method to verify their patients' insurance authorization for treatment with ENBREL.

Sample Letter of Medical Necessity

Below is a sample letter of medical necessity that you can customize for your patients.

Uninsured Patients

You may choose to refer uninsured patients to the ENcourage Foundation®—a nonprofit foundation supported by Amgen and Pfizer that has helped more than 30,000 eligible patients receive ENBREL. For more information, visit www.ENcourageFoundation.com.

Important Safety Information Prescribing Information Medication Guide
Indications
 
Safety Information ISI

Injection demos for your patients

View step-by-step videos that demonstrate 4 convenient options for self-injecting ENBREL.

Watch injection demos

ENBREL Support™ offers financial support to new or continuing eligible patients*

No out-of-pocket costs for 6 months for new ENBREL Support™ card members.

Learn about our program
*Eligibility: Open to patients with commercial prescription insurance. Not open to uninsured patients or patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare including Medicare Part D, Medicaid, etc.) or patients who live in Massachusetts (or where prohibited by law). Restrictions, including monthly maximums, may apply. Offer subject to change or discontinuation without notice.
ENBREL Support (TM) has been a great resource for Donna.
Donna D., ENBREL PsA patient since 2006
 
 
Close
You are leaving Enbrel.com/RheumPro
Please know that Amgen and Pfizer do not endorse and are not responsible for the content included on the site you are about to enter. Click the "Continue" button to proceed.

To return to ENBREL.com, click "Cancel" or close this window.

Privacy Policy  Terms of Use
This site is intended for US Audiences only.
©2011 Amgen, Inc., Thousand Oaks, CA 91320 and Pfizer Inc
Close
E-mail this page to a colleague
Please correct the fields marked in red
Send
This content is for US health care professionals only. Amgen and Pfizer will not use your e-mail address or your colleague's e-mail address for any other purpose. To learn more about our use of your information and your rights, please consult our Privacy Policy.
Close

Send another e-mail
Return to enbrel.com/RheumPro

Close
Notice

The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical practices that are different than those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.

If you are a resident of the United States or one of its territories, or a health care professional practicing your profession in the United States or one of its territories, please click below.

If you are a resident of a country other than the United States, please visit the Pfizer website and the Amgen website to find information about our offices around the globe.
Close
Disease activity vs. structural progression in RA